CompletedNCT01863459
Lisdexamfetamine for Adult ADHD With Anxiety or Depression
About this title
Read the official source — NCT01863459Medication studyAges 18–65Canada
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- HamiltonSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateApril 2013
- Recruitment status
- Completed
- Enrollment listed in the registry
- 42
- Sponsor
- Centre for Anxiety, Attention Deficit and Trauma, Ontario, Canada
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Canada
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT01863459
- Official title
Show the full official title
Lisdexamfetamine Dimesylate in the Treatment of Adult ADHD With Anxiety Disorder Comorbidity
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Hamilton
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Centre for Anxiety, Attention Deficit and Trauma, Ontario, Canada.
Did this study involve medication?
Yes. The study involved medication, including Lisdexamfetamine Dimesylate and placebo.
Who was this study for?
Listed age limits: 18 years to 65 years.
